Lan Wang's research while affiliated with First Affiliated Hospital of China Medical University and other places

What is this page?


This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (6)


Figure 3. Claudin-3 is a positive regulator of cancer stemness in nonsquamous non-small-cell lung carcinoma. (A) Effect of siRNA-mediated claudin-3 knockdown on the percentage of side-population in H460 and H1792. (B) The efficiency of claudin-3 knockdown using semiquantitative RT PCR analysis. (C) Effect of claudin-3 knockdown on the capacities of tumorsphere formation (n = 8 per group). (D) The efficiency of claudin-3 knockdown using shclaudin-3 lentivirus particles. (E) Effect of claudin-3 knockdown on the rates of tumorsphere formation. (F) Effect of claudin-3 knockdown on the rates of tumor formation. Data of SP analysis from triplicates are presented as the mean ± standard deviation, *p < 0.05; **p < 0.01; ***p < 0.001. The p-value for E or F was calculated using the online Extreme Limiting Dillution Analysis (ELDA) online program at http://bioinf.wehi.edu.au/software/elda/.RT PCR: Reverse transcription PCR; SP: Side-population.
Figure 4. Claudin-3 is a positive regulator of cancer stem-like cells-mediated cisplatin resistance in nonsquamous non-small-cell lung carcinoma. (A) Comparison of cisplatin sensitivities between parental H460 cells and H460 tumorspheres. (B) Comparison of cisplatin uptake between parental H460 cells and H460 tumorspheres. (C) Effect of claudin-3 knockdown on cisplatin resistance in H460 tumorspheres. (D) Effect of claudin-3 knockdown on cisplatin uptake in H460 tumorspheres. (E) Effect of claudin-3 knockdown on cisplatin-induced apoptosis-related proteins including caspase-9 and its downstream poly ADP-ribose polymerase (PARP) in H460 tumorspheres. Data of apoptosis and ICP MS analysis from triplicates are presented as the mean ± standard deviation, ***p < 0.001.
Targeting Claudin-3 Suppresses Stem Cell-Like Phenotype in Nonsquamous Non-Small-Cell Lung Carcinoma
  • Article
  • Full-text available

February 2019

·

116 Reads

·

15 Citations

Lung Cancer Management

·

Wu Yin

·

Heliang Ma

·

[...]

·

Lan Wang

Aim To determine the role of claudin-3 in cancer stemness in nonsquamous non-small-cell lung carcinoma (NSCLC). Materials & methods In vitro/vivo extreme limiting dilution analysis and the side population assay were used to investigate the role of claudin-3 in regulating cancer stemness in nonsquamous NSCLC. Results & conclusion Claudin-3 depletion decreased the formation rates of spheres and tumors and increased cisplatin sensitivity. Claudin-3 was also identified as one downstream target of estrogen receptor-α in regulating cancer stemness. Moreover, targeting CLDN-3 transcription by small molecules including withaferin A, estradiol and fulvestrant suppressed cancer stemness and reversed chemoresistance. These results demonstrated claudin-3 is one positive regulator of cancer stemness in nonsuqamous NSCLC.

Download
Share


Fig 1. Analysis of LNX1 and CSC markers in CRC SP and non-SP cells. (A) Sorting of SP and non-SP cells using BD Aria software. The verapamil group was set as the negative control. (B) and (C) are the western blot and the semi-quantitative RT PCR analysis of genes (LNX1 as well as CSC markers in CRC including LGR5, CD133, ABCB5 and ALDH1A1). 
Table 1 . Effect of LNX1 knockdown on the tumor formation rate using the HT29 cell line.
Fig 3. CXADR functions as a downstream CSC-meditator of LNX1. (A) Targets screening of LNX1 using SP analysis. B, C, D represent the expression analysis of CXADR and LNX1 respectively in HT29 compared with HT29-derived colonospheres (A); in SP and non-SP group(B); in various CRC cell lines(C).(E)Effect of LNX1 knockdown on CXADR level. (F-1) Effect of double knockdown of CXADR and LNX1 on the percentage of SP. (F-2) The inhibition percentage of SP frequency by LNX1 in the presence or absence of CXADR. (F-3) The inhibition percentage of SP frequency by CXADR knockdown in the presence or absence of LNX1. Data from triplicates are presented as the mean±SD, *P<0.05, **P<0.01, ***P<0.001. https://doi.org/10.1371/journal.pone.0188665.g003 
Fig 4. LNX1-based drug screening to suppress cancer stemness in CRC. (A) Effect on small molecules on LNX1 transcription. (B) Effect of tamoxifen on the LNX1 protein level in HT29 and Colo205 cell lines detected by western blot. (C)Effect of tamoxifen and LNX1 knockdown on the capacities of colonosphere formation (n = 8 per group). (D) Effect of tamoxifen and LNX1 knockdown on the rates of colonosphere formation (p value was calculated using the online ELDA software). Data from triplicates are presented as the mean±SD, *P<0.05, **P<0.01, ***P<0.001. https://doi.org/10.1371/journal.pone.0188665.g004 
Fig 5. Probable mechanisms underlying tamoxifen therapy targeting ER-positive cells against breast cancer. (A) Effect of ER knockdown on the LNX1 level, data was obtained from the curated Datasets in the Gene Expression Omnibus (GEO) repository(GDS4061). (B) Schematic presentation of the predicted mechanisms underlying tamoxifen therapy targeting ER-positive cells against breast cancer, the broken lines indicate the possible cases at different circumstance. In ER-positive cells, tamoxifen could trigger the expression of LNX1 and exert its anti-tumor function, which could be abolished in ER-negative cells due to the restricted LNX1 level. 
Suppression of cancer stemness by upregulating Ligand-of-Numb protein X1 in colorectal carcinoma

November 2017

·

121 Reads

·

10 Citations

PLOS ONE

PLOS ONE

Cancer stem-like cells (CSCs) have been reported to play major roles in tumorigenesis, tumor relapse, and metastasis after therapy against colorectal carcinoma (CRC). Therefore, identification of colorectal CSC regulators could provide promising targets for CRC. Ligand-of-Numb protein X1 (LNX1) is one E3 ubiquitin ligase which mediates the ubiquitination and degradation of Numb. Although several studies indicate LNX1 could be a potential suppressor of cancer diseases, the functions of LNX1 in mediating cancer stemness remain poorly understood. In this study, LNX1 was identified as a negative regulator of cancer stemness in CRC, which was downregulated in colonospheres or side population (SP) cells. Furthermore, the coxsackievirus and adenovirus receptor (CXADR) was found to be one critical downstream mediator of cancer stemness regulated by LNX1. Interestingly, the anti-breast cancer drug tamoxifen was found to be an agonist of LNX1 and suppress cancer stemness in CRC. In sum, this study provided the evidences that LNX1 signaling plays important roles in regulating the stemness of colon cancer cells.


S1 Fig

November 2017

·

13 Reads

Analysis of the function of LNX1 in mediating cancer stemness in colorectal carcinoma cell line Colo205. (A) Effect of LNX1 knockdown on the percentage of SP in Colo205. (B) Effect of LNX1 knockdown on the capacities of colonosphere formation (n = 8 per group). (C) Effect of LNX1 knockdown on the rates of colonosphere formation (p value was calculated using the online ELDA software). (D) The efficiency of LNX1 knockdown using two shLNX1 constructs. Data from triplicates are presented as the mean±SD, *P<0.05, **P<0.01, ***P<0.001. (TIF)



Citations (2)


... Similarly, the suppression of CLDN3 in non-small-cell lung cancer decreased cancer stemness and improved chemosensitivity [182]. CLDN3 and CLDN4 also regulate cisplatin sensitivity in ovarian cancer cells via copper transporter (CTR1), while CLDN7 enhances cisplatin sensitivity in lung cancer cells via the caspase pathway [183]. ...

Reference:

Claudins in Cancer: A Current and Future Therapeutic Target
Targeting Claudin-3 Suppresses Stem Cell-Like Phenotype in Nonsquamous Non-Small-Cell Lung Carcinoma

Lung Cancer Management

... Moreover, tamoxifen inhibits ubiquitination and degradation of cyclin B1 by inhibiting ERα-activated UBE3C, which inhibits the proliferation of BC [84]. In colorectal carcinoma (CRC) and PCa, tamoxifen can also inhibit cancer development through UPS [85,86]. The E3 Ligand-of-Numb protein X1 (LNX1) can interact with substrate proteins, such as Numb protein, through its PDZ domain to enable degradation of substrate proteins via UPS, thereby inhibiting stemness [85]. ...

Suppression of cancer stemness by upregulating Ligand-of-Numb protein X1 in colorectal carcinoma
PLOS ONE

PLOS ONE